Ashley ACA - ImmuPharma PLC Group Secretary
| IMM Stock | 1.17 0.03 2.50% |
Executive
Ashley ACA is Group Secretary of ImmuPharma PLC
| Address | 1 Bartholomew Close, London, United Kingdom, EC1A 7BL |
| Phone | 44 20 7206 2650 |
| Web | https://www.immupharma.co.uk |
ImmuPharma PLC Management Efficiency
The company has return on total asset (ROA) of (0.43) % which means that it has lost $0.43 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.112) %, meaning that it generated substantial loss on money invested by shareholders. ImmuPharma PLC's management efficiency ratios could be used to measure how well ImmuPharma PLC manages its routine affairs as well as how well it operates its assets and liabilities. At present, ImmuPharma PLC's Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 5.2 M, whereas Non Current Assets Total are forecasted to decline to about 1.4 M.Similar Executives
| Found 14 records | EXECUTIVE Age | ||
| Alfredo Pascual | Seed Innovations | 36 | |
| Simon Edwards | European Metals Holdings | N/A | |
| Ian Farrelly | Quadrise Plc | N/A | |
| Henko Vos | European Metals Holdings | N/A | |
| Robert Naylor | Intuitive Investments Group | 50 | |
| David FCA | Quadrise Plc | N/A | |
| David Scott | Quadrise Plc | N/A | |
| Patrick Brunelle | Quadrise Plc | N/A | |
| LLB BCom | European Metals Holdings | N/A | |
| Norbert Teufelberger | Seed Innovations | 59 | |
| Mark Collingbourne | Intuitive Investments Group | 58 | |
| Bernard Johnston | Quadrise Plc | N/A | |
| Grant Harman | European Metals Holdings | N/A | |
| Philip Hill | Quadrise Plc | N/A | |
Management Performance
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 |
ImmuPharma PLC Leadership Team
Elected by the shareholders, the ImmuPharma PLC's board of directors comprises two types of representatives: ImmuPharma PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmuPharma. The board's role is to monitor ImmuPharma PLC's management team and ensure that shareholders' interests are well served. ImmuPharma PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmuPharma PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| XIV FCCA, Chairman CEO | ||
| Lisa Baderoon, Head Director | ||
| Laura MauranAmbrosino, Chief Biotech | ||
| Timothy MBA, COO Director | ||
| Sbastien Goudreau, Chief Biotec | ||
| Ashley ACA, Group Secretary | ||
| MD PharmD, Head Development | ||
| Lara SuchestonCampbell, Head Affairs |
ImmuPharma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmuPharma PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 4.77 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Shares Owned By Insiders | 48.33 % | ||||
| Shares Owned By Institutions | 14.35 % | ||||
| Price To Book | 1.85 X | ||||
| Price To Sales | 60.75 X | ||||
| Gross Profit | 118.35 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.